French drug giant Sanofi is accusing
EpiPen maker Mylan of tactics meant to squelch competition from a rival epinephrine device.
Rajiv Malik, president and executive director at
EpiPen maker Mylan (essentially the company's number two exec), has been named in a wide - ranging civil suit alleging drug price collusion by numerous prominent generic drug makers.
Not exact matches
Rep. Jason Chaffetz, a Utah Republican, and Rep. Elijah Cummings, a Maryland Democrat, have sent the
maker of the
EpiPen a letter requesting additional documents clarifying the company's pricing structure.
While the drug
maker has responded to the massive backlash over its extravagant price increase on the device by boosting its patient assistance programs and introducing an authorized generic
EpiPen version at half the cost, CVS» topline price will still be significantly cheaper.
Mylan, already the most dominant
maker of epinephrine auto - injectors, now enjoys a near - monopoly on the market since Auvi - Q's withdrawal: After the recall,
EpiPen's market share immediately jumped from 85 % to 95 % at the end of last year.
NEW YORK — Today, Attorney General Eric T. Schneiderman announced his office has commenced an investigation into Mylan Pharmaceuticals Inc, the
maker of
EpiPens.
City and state teachers unions have been funneling millions of dollars into a grassroots protest group that has been targeting
EpiPen manufacturer Mylan — even though their pension funds are heavily invested in the drug
maker.
Drug
maker Mylan said it will offer a generic version of the life - saving allergy treatment
EpiPen for half the list price of the brand - name treatment after it became the center of a national controversy over skyrocketing drug prices.